Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioventixLSE:BVXP 61 9-Day RSI is 34.86 as of Jul. 20, 2026. GuruFocus rates LSE:BVXP with a GF Score™ of 61/100 and a GF Value™ of £35.91 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,422 Biotechnology companies, Bioventix ranks better than 80.1% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-20), Bioventix's 9-Day RSI is 34.86.
The industry rank for Bioventix's 9-Day RSI or its related term are showing as below:
LSE:BVXP's 9-Day RSI is ranked better than 80.1% of 1422
companies
in the Biotechnology industry
Industry Median: 44.36
vs LSE:BVXP: 34.86
Bioventix (LSE:BVXP) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Bioventix 9-Day RSI Related Terms
LSE:BVXP vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Bioventix's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventix 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioventix's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Bioventix's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventix (LSE:BVXP) has a 9-Day RSI of 34.86 as of Jul. 20, 2026. According to the industry distribution chart, Bioventix ranks #283 out of 1422 companies in the Biotechnology industry, placing it in the top 19.9%.
Is Bioventix's 9-Day RSI too high?
Bioventix's current 9-Day RSI is 34.86. The Biotechnology industry median 9-Day RSI is 44.36. Bioventix's value of 34.86 is 21.4% below this industry median. Based on the distribution chart, Bioventix ranks #283 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventix has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bioventix ranks #283 out of 1422 companies for 9-Day RSI. This places Bioventix in the top 20% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 44.36. Bioventix's value of 34.86 is 21.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 44.36, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioventix's current 9-Day RSI of 34.86 is 21.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 44.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioventix's current 9-Day RSI is 34.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (LSE:BVXP) is currently considered Significantly Undervalued. The stock's GF Value™ is £35.91, compared to a current price of £15.50 — trading 56.8% below its estimated fair value. The current 9-Day RSI is 34.86 and 21.4% below the Biotechnology industry median of 44.36. Bioventix's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Bioventix (LSE:BVXP), the current 9-Day RSI is 34.86 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventix (LSE:BVXP) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventix stock appears to be undervalued.
The current stock price of £15.50 is trading 56.8% below its estimated GF Value™ of £35.91.
GuruFocus considers Bioventix to be Significantly Undervalued.
Key valuation signals for LSE:BVXP:
9-Day RSI: 34.86
GF Value™: £35.91 vs. price of £15.50 (56.8% below fair value)
Industry Position: 21.4% below the Biotechnology median (#283 of 1422)
No single metric tells the full story. See the LSE:BVXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
61GF Score
Get the complete analysis for LSE:BVXP
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BVXP has been successfully added to your 
